12 February 2019
Visiongain has launched a new pharma report Vaccines Manufacturers Market Report : Merck & Co., Sanofi, Pfizer, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Emergent Biosolutions, Other Companies
The world vaccines market is set to grow steadily over the next 10 years. This growth is mainly driven by a global ageing population, as the elderly are more prone to contracting infections due to their pre-existing health conditions and a weak immune system. Demand from the emerging markets further drive growth as their middle class gets wealthier and demand better healthcare systems, furthermore the high birth rates in the emerging markets will feed the paediatric vaccines segment. Moreover, the vaccine industry benefits from strong research and development leading to continuous innovation. Technological advancements will be made in vaccine delivery and administration. As a result, the development of more efficient technology will reduce costs of vaccine production, making the entire manufacturing and supply chain more efficient.
The lead analyst of the report commented "Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development. New target sites, ways of generating an immune response and method of administration are already being investigated and, in some cases, successfully implemented. Further progress is expected to be made in this field as companies look for other ways to gain a competitive edge over their rivals, which could just be another way of administering an existing vaccine. This factor is expected to provide strong growth opportunities to vaccines manufacturers."
Leading companies featured in the report include Astellas Pharma Inc., AstraZeneca, Bavarian, Nordic, CSL Ltd., Emergent Biosolutions, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline PLC, Inovio Pharmaceuticals and others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.
03 December 2020
Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.
03 December 2020
Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.
03 December 2020
All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.